MRIGlobal Wins Subcontract To Evaluate New Treatment For Wound Care
Work Supports Government Project with Argentum Medical.
KANSAS CITY, Mo., Oct. 28, 2013 /PRNewswire-USNewswire/ -- MRIGlobal today announced that it will work with Argentum Medical LLC, which was awarded a $7.8 million, 24-month contract by the Department of Health and Human Services, Biomedical Advanced Research and Development Authority.
MRIGlobal will support Argentum Medical by developing comprehensive treatment regimens and models to evaluate the efficacy of antimicrobial burn contact dressings as advanced treatments for wounds caused by chemical threat agents.
The project includes options for additional work in efficacy testing using stringent Good Laboratory Procedures, up to $16.5 million over a five-year period, if milestones are met.
Argentum Medical, of Geneva, Ill., is a leading manufacturer of metallic silver based antimicrobial burn, wound, and trauma dressings brand named Silverlon. The Silverlon® technology permanently plates metallic silver to the surface of the dressing allowing the surface to continual delivery silver ions for 7 days of use on serious skin injuries.
"We're very pleased to support Argentum Medical with this important project to provide the government with effective medical countermeasures to chemical threats," said Robert P. Casillas, Ph.D., Vice President of Global Health Security.
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSOL00201300019C.
About Argentum Medical
Argentum Medical pioneered the use of metallic silver-plated nylon to help fight infection and facilitate wound healing. Specializing in the development of innovative products made from silver-plated nylon, Argentum Medical will continue to explore new applications and markets for its Silverlon technology in keeping with its corporate mission to improve clinical outcomes.
For more information, visit www.mriglobal.org.